All In Biotech

Drug Trial Radar · NCT02508532

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

250

Actual

Start

Aug 2015

Primary completion

Mar 6, 2020

Study completion Jun 3, 2021

Sponsor

Sponsor type
Industry
First posted
Jul 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).

Conditions

  • Gastrointestinal Stromal Tumors (GIST)
  • Other Relapsed or Refractory Solid Tumors

Interventions

  • AvapritinibDrug

    avapritinib tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of AvapritinibTime frame: Cycle 1 (28 days) of treatment
  2. Parts 1 and 2: Number of Patients With Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: AEs were collected from the start of study drug until 30 days after the last dose, SAEs were collected from the date of the informed consent signature until 30 days after the last dose of study drug, up to 5 years
  3. Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.

Locations

19 sites in 10 countries. Site status is shown where the registry gives one.

  • Scottsdale Healthcare Hospitals DBA HonorHealth

    Scottsdale, Arizona

  • Sarcoma Oncology Center

    Santa Monica, California

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Cancer Treatment Centers of America

    Atlanta, Georgia

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Oregon Health and Science University

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Leuven Cancer Institute University Hospitals Leuven

    Leuven, Belgium

  • Centre Leon Berard

    Lyon, France

  • Institut Gustave Roussy

    Paris, France

  • University of Duisburg-Essen

    Essen, Germany

  • Fondazione IRCCS - Istituto Nazinale dei Tumori

    Milan, Italy

  • Erasmus MC Cancer Institute

    Rotterdam, Netherlands

  • Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie

    Warsaw, Poland

  • Asan Medical Center

    Seoul, South Korea

  • Vall d' Hebron Institute of Oncology (VHIO)

    Barcelona, Spain

  • Royal Marsden Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.